True North Therapeutics Secures $22,000,000 Series A Funding Round

  • Feed Type
  • Date
    6/17/2014
  • Company Name
    True North Therapeutics
  • Mailing Address
    951 Gateway Blvd. South San Francisco, CA 94080 USA
  • Company Description
    True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The company’s lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis.
  • Website
    http://www.truenorthrx.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $22,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    Proceeds from the financing will be used to advance True North’s lead drug candidate, TNT009, into clinical development, with the initiation of the first human clinical trial planned for early 2015.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor